Hillsdale Investment Management Inc. Acquires Shares of 17,003 Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Hillsdale Investment Management Inc. bought a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 17,003 shares of the company’s stock, valued at approximately $226,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Westside Investment Management Inc. grew its stake in Eton Pharmaceuticals by 5.7% during the 3rd quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock worth $3,711,000 after buying an additional 33,275 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Eton Pharmaceuticals by 13.5% in the third quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock valued at $1,637,000 after acquiring an additional 32,365 shares during the period. Parkman Healthcare Partners LLC grew its position in shares of Eton Pharmaceuticals by 2.8% during the third quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock worth $1,561,000 after acquiring an additional 7,029 shares during the last quarter. Wasatch Advisors LP acquired a new position in shares of Eton Pharmaceuticals in the 3rd quarter valued at $1,431,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Eton Pharmaceuticals by 230.5% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company’s stock valued at $2,862,000 after acquiring an additional 149,864 shares during the period. Institutional investors and hedge funds own 27.86% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on ETON shares. B. Riley reissued a “buy” rating and set a $24.00 price objective (up from $21.00) on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th. HC Wainwright reissued a “buy” rating and set a $33.00 price target on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. Finally, Craig Hallum upped their price objective on Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, March 19th.

Eton Pharmaceuticals Stock Performance

Shares of Eton Pharmaceuticals stock opened at $14.79 on Tuesday. Eton Pharmaceuticals, Inc. has a one year low of $3.03 and a one year high of $18.41. The company has a market cap of $396.64 million, a P/E ratio of -67.23 and a beta of 1.37. The firm has a fifty day moving average of $15.59 and a two-hundred day moving average of $11.71.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02). The firm had revenue of $11.65 million during the quarter, compared to analysts’ expectations of $10.53 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. As a group, equities analysts predict that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current year.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.